BR102375 

BR102375 is a non-TZD peroxisome proliferator-activated receptor γ (PPAR γ) full agonist for the treatment of type 2 diabetes, reveals EC₅₀ value of 0.28 μM and A_max ratio of 98%^[1].

BR102375 (Compound 18) (10 μM) increases gene expression levels relevant to PPARγ activation and enhances glucose uptake under insulin stimulation^[1].
BR102375 (Compound 18) (10 nM, 100 nM, 1 μM; 6 days, 14 days) shows a concentration-dependent, insulin-sensitive effects on adipogenesis^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

BR102375 (Compound 18) has decent efficacy on mouse diabetes model^[1].
BR102375 reveals significant suppressive effect on random blood glucose increase(75 mpk, p.o., bid), shows decent effect on insulin resistance on Oral glucose tolerance test (OGTT) and discloses similar findings in body weight gain almost identical to Pioglitazone^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

554.64

C₃₁H₃₄N₆O₄

2366255-59-4

CCCCC(N1CC2=CC=C(C3=C(C4=NOC(N4)=O)C=CC=C3)C=C2)=NC(C)=C(CC5=NC(C(C)(C)C)=NO5)C1=O

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Choung W, et al. Discovery of BR102375, a new class of non-TZD PPARγ full agonist for the treatment of type 2 diabetes. Bioorg Med Chem Lett. 2019 Jun 19. pii: S0960-894X(19)30407-X.  [Content Brief]

  [2]. Yan Zhu, et al. Protective Role of Long Noncoding RNA CRNDE in Myocardial Tissues From Injury Caused by Sepsis Through the microRNA-29a/SIRT1 Axis. Life Sci. 2020 May 27;117849.  [Content Brief]